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Preface  
The multi-step process of cancer progresses over many years. The prevention of muta-
tions by DNA repair pathways led to an early appreciation of a role for repair in cancer 
avoidance. However, the broader role for the DNA damage responses (DDR) emerged 
more slowly. We reflect on how our understanding of the steps leading to cancer unrav-
elled, focusing on the role of the DDR. We consider how our current knowledge can be 
exploited for cancer therapy. 
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Introduction. 
Carcinogenesis has long been recognised as a state of uncontrolled growth of our own cells. 
The earliest models proposed the notion of a mutational event, even before Watson and 
Crick’s seminal discovery of the structure of DNA. By the 1980s, the initiation step of 
carcinogenesis was understood to necessitate the generation of mutations, with the concept of 
environmental mutagens and failed DNA repair being central to many models. In contrast, an 
understanding of the basis underlying tumour progression or outgrowth unfolded relatively 
slowly and an appreciation of the critical role played by the DNA damage responses (DDR) 
took even longer to solidify.  Indeed, even as the twenty first century began, DNA repair 
remained a relatively insignificant component of the broad field of cancer research.  It is now 
appreciated that tumour progression necessitates the down-regulation of damage surveillance 
mechanisms and an increase in genetic/epigenetic instability to achieve uncontrolled 
proliferation and the adaptability associated with aggressive tumours. In this review, we 
describe the early concepts of mutation and cancer that predate knowledge of the structure of 
DNA, and how the links between mutagenesis and carcinogenesis were established. We go 
on to discuss the early studies of viral oncogenes and the insights they provided into 
carcinogenesis, leading to the much more recent but critical understanding that oncogene 
induced replicative stress promotes genomic instability. We provide a perspective for how the 
notions of tumour initiation and progression emerged, describing the key concept that tumour 
progression is inexorably linked to disruption of the DNA damage response (Figure 1). 
Finally, we consider the ironic conundrum that, while targeting the DDR can provide 
treatment strategies, it is the mis-regulation of the DDR that is often the route by which 
tumour cells evade therapy.  
 
The emerging notion that mutagenesis underlies carcinogenesis 
In the early 20th century, long before the structure of DNA was defined, Boveri proposed that 
a cancer cell was a changed normal cell and advanced the theory that tiny microscopic bodies 
called chromosomes were abnormally distributed in cancer1. As the notion of hereditary units 
or “determinants” and later “genes” emerged alongside their relationship to chromosomes, 
the idea that permanent changes to these “genes” (defined as mutations) could underlie herit-
able biological phenotypes became conceptualised. From there, it did not require a great leap 
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to appreciate that such mutations might underlie the origin of the biological variation ob-
served in cancer (reviewed in2).  In the 1930s it was recognised that a normal human cell has 
46 chromosomes but in cancers they are abnormally distributed and frequently in excess of 
46. Paradoxically, non-tumorous cells and plants with an asymmetric or unbalanced chromo-
some distribution grew less vigorously than normal cells, whereas cancer cells were charac-
terised by an enhanced growth capacity. Work with Drosophila had revealed that chromo-
some aberrations correlated with the formation of genetic variants and, in 1927, Muller 
demonstrated that exposure of Drosophila to X-rays induced “transmutation” of a gene, caus-
ing both visible chromosome aberrations and heritable phenotypic variations3, 4.  
Intriguingly, in 1775, Percival Pott made the seminal observation that there was a 
high incidence of scrotal cancer in boys who assisted chimney sweeps and linked this finding 
to exposure to soot5, 6, 7. This represented the first evidence for a work-related and environ-
mental cause of cancer. By 1955, shortly following the discovery of the DNA structure, it 
was well appreciated that exposure to chemical mutagens could enhance mutation rates, with 
a correlation between mutagenesis and carcinogenesis being hypothesised though certainly 
not consolidated2. Remarkably, the suggestion that there could be cancer susceptibility genes 
was also proposed2. 
 
The link between mutagens, carcinogens and DNA.  
With the structure of DNA defined in 19538, 9 and the understanding that genetic mutation 
represented a change in the chemical structure of the DNA molecule, the first clear 
connections between the processes of mutation and carcinogenesis were made by Phil 
Lawley, working at the Chester Beatty Research Institute (now the Institute of Cancer 
Research). Working with Peter Brooks, he showed that many classic alkylating agents 
worked by reacting directly with DNA to form stable chemical adducts that could disrupt the 
template function of the DNA molecule10, 11. This led directly to their seminal observation 
that the carcinogenicity of polycyclic aromatic hydrocarbons – the likely causative agents of 
scrotal cancer in those chimney sweeps and also the classic carcinogenic components of 
tobacco smoke  - was directly correlated with their ability to form DNA adducts, providing an 
unambiguous link between the initiation of cancer and chemical changes to DNA12. The 
significance of these early findings and functional link between mutagenesis and 
carcinogenesis is demonstrated by the development and later adoption of tests classifying 
carcinogens on the basis of this relationship13. 
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Lawley and Brooks were also amongst the first to document biological repair 
processes for chemical and environmental damage to DNA10, a theme very actively adopted 
by many laboratories14-19 (see also20 for a review). Over the next thirty years a plethora of 
repair pathways for chemical lesions of DNA, primarily identified in bacteria, was 
progressively revealed. Subsequently, human homologues for many of these repair enzymes 
and pathways were identified. For the most part, these systems - or possible defects in them - 
were not associated with the initiation or the progression of cancer in any significant way. 
There was, however, an emerging recognition of the role that DNA repair mechanisms might 
play in mediating resistance to alkylating agents used for cancer chemotherapy21. 
 
Insight from DNA repair disorders. 
A significant exception to this picture was the seminal observation by Jim Cleaver in 1969 
who was studying the rare (1:250,000) autosomal recessive cancer predisposition syndrome, 
xeroderma pigmentosum (XP). XP patients have a 1000 fold increased chance of skin cancer, 
but display almost normal levels of tumour presentation in other tissues22. Cleaver found that 
cells from XP patients were defective in the ability to repair DNA damage caused by 
ultraviolet (UV) light23. The DNA repair defects in most (though not all) XP cells were 
subsequently shown to result from mutations in components of the human nucleotide excision 
repair (NER) system22, 23. Critically, this process is responsible for the removal of helix-
distorting UV-photodimers from DNA, explaining the highly specific skin cancer 
predisposition of XP patients.  
A second clear example of a defective DNA repair pathway being responsible for 
cancer initiation emerged in the early 1990s: patients with Lynch Syndrome (aka hereditary 
non-polyposis colorectal cancer) - a familial pattern of colorectal cancer characterised by 
microsatellite repeat instability – were found to carry mutations in the human homologues of 
the bacterial mismatch repair (MMR) proteins MutS and MutL24-27. Both of these inherited 
diseases reinforced a model for cancer initiation in which random unrepaired point mutations 
eventually result in an alteration to the coding sequence of a key oncogene or tumour 
suppressor, initiating the first step in cell proliferation and enabling a subsequent cascade of 
mutagenic events in these precancerous cells. 
A prediction arising from these studies of patients with hereditary predisposition to 
cancer was that mutations in DNA repair genes might frequently arise in cancer cells. As will 
be discussed below, this has certainly proved to be the case. However, the early studies were 
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carried out when there was not a comprehensive understanding of DNA repair pathways and 
DNA damage responses in humans and when sequencing technology was significantly less 
sophisticated, and thus the attempts to address this prediction were not very revealing. In 
these early studies, polymorphisms and tumour-associated mutations in DNA base excision 
repair enzymes such as 8-oxoguanine DNA glycosylase (Ogg1) and APE1 and in components 
of the downstream generic XRCC1-based part of base-excision repair were identified in some 
tumour cells28, 29. However the penetrance of such polymorphisms is weak and the clinical 
relevance of these to the overall cancer burden was unclear30. Subsequently several complex 
conditions in which cancer predisposition is a feature, such as Bloom’s and Werner’s 
syndromes, and Fanconi anaemia, have been shown to arise from genetic defects in DNA 
repair systems, as have subsets of familial breast, ovarian, prostate and pancreatic cancers31-
36.  
 
Contribution from studies of radiation exposure. 
That X-ray exposure confers an increased risk of malignant disease, including leukaemia and 
skin cancers, became accepted within a few decades after the discovery of X-rays in 1895.  
However, radiation studies were disappointing when it came to gaining mechanistic insight 
into the aetiology of cancer. Nonetheless, reports by the International Committee on 
Radiological Protection (ICRP) and Scientific Committee on the Effects of Atomic Radiation 
(UNSCEAR) provide an invaluable source for rationalising the emerging concepts (e.g.37). In 
particular, the analysis of the atomic bomb survivors provided a wealth of epidemiological 
data, such as revealing that there can be a long induction period prior to the onset of cancer, 
and in UNSCEAR 1958 it was concluded that radiation-induced mutations are biologically 
relevant for carcinogenesis37. However, the relationship between chromosome 
aberrations/rearrangements (which X-rays avidly induce) and point mutational changes 
(which X-rays inefficiently induce) remained puzzling.  A further important concept emerged 
from these early radiation studies: the carcinogenic effect of radiation does not correlate with 
its cell-lethal effects. It was observed that, while cell killing consistently increased as the 
linear energy transfer (LET – a measure of radiation quality) increased because of the 
enhanced complexity of the DNA damage, the frequency of cell transformation, a correlate 
for carcinogenicity, did not follow the same pattern: it increased initially but peaked and 
decreased at very high LET. 
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These early studies evaluating the response to radiation damage raised an additional 
dilemma: cells from ataxia telangiectasia (A-T) patients, a cancer prone and profoundly 
radiosensitive human disorder, were not hyper-mutated by X-rays and, despite their marked 
radiosensitivity, A-T cells did not display an obvious defect in repairing X-ray induced DNA 
damage. The cause of this apparent paradox only became clear after the discovery that the 
gene defective in A–T patients, ATM, encodes a protein kinase that triggers a signalling 
cascade that regulates cell cycle arrest and cell death responses rather than a DNA repair 
enzyme. (Nonetheless, ATM signalling can indirectly influence DNA repair processes). This 
important distinction between signalling responses and direct DNA repair has proved to be 
critical in the context of cancer avoidance. Indeed, the wider response to DNA damage 
(known as the DNA Damage Response; DDR) is now usefully sub-divided into damage 
response signalling and direct DNA repair. Significantly, the DDR signalling response 
frequently has a greater impact on genomic stability in response to DNA damage in contrast 
to DNA repair pathways, which more dramatically influence survival.  
 
Battles between competing models and research fields. 
The concept that cancer involved at least one genetic mutation was well accepted by the 
1970s. However, the notion that oncogenesis is a multistage process was proposed by Ber-
enblum and Shubik as early as 1948, based on studies showing that tumour cells induced by 
carcinogen treatment could remain in a latent stage until outgrowth was promoted by subse-
quent treatment38. From 1970 through to the turn of the century, a range of studies including 
epidemiological analysis of atomic bomb survivors, studies in mice and cell culture models of 
transformation all provided strong evidence that cancer was a multistage process39. It was un-
derstood that cancer incidence increased dramatically with age and that exposure to ionising 
radiation brought forward the age of onset of most cancers, but still involved a marked lag 
period. Two contrasting models arose to explain these observations: cancer involved a muta-
genic initiation step, following by a long period of outgrowth, or cancer was a multistage 
process, involving multiple mutational hits40, 41. Slowly, the concept of a multistage process 
became the predominant model, supported in part by the observation that the transformation 
of cultured cells occurred more rapidly, and at higher frequency, if cells were transfected with 
two versus a single oncogene42 (see for example the review written in 199343).  
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The marked number of mutational and chromosome changes present in cancer cells, 
evident from the early studies, and the fact that the median number of rearranged chromo-
some arms correlated with cancer prognosis44 played  significant roles in shaping models and 
thoughts. The multistep nature of carcinogenesis coupled with the evident chromosome 
changes led to several models which, at their core, involved clonal evolution, i.e. progressive 
selection of rare mutated cells45.  Two extreme models were proposed. In the first, carcino-
genesis required the activation of multiple oncogenes and/or the inactivation of tumour sup-
pressor genes and each rearrangement contained an amplification, or loss, of a specific gene. 
This was supported by the identification of p53 as a tumour suppressor, the loss of which en-
abled the evolution of rare mutated cells46.   Such hypotheses also suggested that elevated ge-
nome instability would not necessarily be required (each acquired mutation could increase 
growth potential). The alternative extreme model suggested that the vast majority of rear-
rangements had no phenotypic consequence, but rather represented “passenger mutations”. 
To explain this, the notion of a mutator phenotype was proposed, which though controversial, 
remains actively discussed as a working model today47-49.  Current advances in single cell 
sequencing procedures are demonstrating the enormous sequence changes between cells 
within a single tumour, and have shown that the level of plasticity within a tumour correlates 
with aggression50 . However, these findings do not entirely allow the distinction to be drawn 
as to whether multiple mutations and a mutator phenotype are causal of malignancy or rather 
a consequence of malignancy. Critical to this is deducing the stage at which instability arises. 
In parallel to the emerging concepts that carcinogenesis necessitated DNA sequenc-
ing changes, thinking also focused on the fact that cancer is predominantly a disorder of 
deregulated growth likely involving changed patterns of differentiation or de-
differentiation. By this time it was generally accepted that differentiation during develop-
ment was epigenetic51. This led to experiments where tumour cell nuclei with a normal 
modal chromosome number were transplanted into anucleated eggs to generate adult ani-
mals52-54. Significantly, such injections allowed for the development of normal animals, 
potentially demonstrating developmental totipotency that suggested a non-mutational basis 
for transformation to malignancy. In the context of current knowledge, such experiments 
were likely flawed, or at least exceptional. However, developments in the DNA methyla-
tion field provoked research into methylation changes associated with cancer, leading to 
proposals that methylation changes drive expression changes and thus cancer 
development55.  Indeed, we now know that epigenetic changes are commonly found in 
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cancer cells and provide a route, like mutagenesis, to changed gene expression and thus 
function. 
During the latter part of the 20th century the different models tended to be consid-
ered as exclusive, generating unfortunate conflicts that also influenced the battle that 
emerged regarding a viral aetiology for cancer. The identification of numerous oncogenes 
from work on viruses, plus revelations that many viruses encode proteins related to human 
growth factors whose expression could promote deregulated growth, led to a widespread 
belief that the majority of cancers were of viral origin56, 57. The viral community, in part 
because of its huge contributions to oncogene discovery (see below), gained significant 
influence. In hindsight, the strength of the arguments made by the viral community dis-
couraged full consideration of a genomic instability model for cancer development. With 
our current knowledge, a model proposing a genomic instability origin for cancers would 
predict that viral infections could be carcinogenic, given the ability of many viruses to sub-
vert components of the DDR (e.g.58). Any remaining controversy ultimately depends on the 
magnitude of the viral aetiological contribution, which cannot, for example, easily explain 
diet and smoking related tumorogenesis. 
 
Oncogenes, their significance and oncogene induced stress. 
Oncogenes were first identified by studying retroviruses: the prototype oncogene, src, is a 
chicken Rous sarcoma virus gene that was hijacked from the chicken genome59. It soon 
became clear that a defined, but significant, number of oncogenes were involved in cancer 
initiation and that oncogene expression caused neoplastic transformation60. In the early 1990s 
it was reported that genome instability occurred rapidly after Ras oncogene expression and 
subsequent reports demonstrated that this was not an isolated phenomenon61-63. By the late 
1990s, it had been shown that p14ARF, the product of a second open reading frame (ORF) 
within the INK4 locus that binds to Mdm2 and upregulates p53, responded to Ras and Myc 
expression by activating the p53 - p21 pathway to drive senescence/apoptosis64, 65. Since it 
was known that DNA damage treatment activated p53 - p21 to drive senescence/apoptosis, 
this led to the suggestion that oncogene expression directly caused DNA damage66.  
It was initially proposed that deregulated metabolism due to Myc-dependent 
transcription increased reactive oxygen species (ROS) and thus DNA damage, an idea 
consistent with models postulating that a mutator phenotype underpinned cancer 
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development66. The link between oncogene expression and DNA damage and/or its repair 
generated significant interest: for example, Myc expression in non-cancerous cells was shown 
to reduce DNA repair efficiency and induce p53 and its ATM-ATR dependent (but p14ARF-
independent) phosphorylation67, 68. Concurrently, p53 and p21 were shown to prevent cell 
proliferation when Cyclin E/Cdk2 was over-expressed and that this operated through an 
ATM/ATR-dependent and p14ARF independent mechanism69. Cyclin E expression had been 
previously shown to cause chromosome instability70 and later it was demonstrated to interfere 
with replication71. The scene was thus set: oncogene-induced proliferation of otherwise 
normal cells perturbed DNA replication mechanisms, producing measurable DNA damage 
and genome rearrangements and activating p53 - p21 via ATM/ATR-dependent mechanisms. 
In 2005, two key papers clearly demonstrated both the activation of DDR signalling, 
including proteins required for cell cycle checkpoint arrest, and increased DNA damage 
markers in precancerous tissue and proposed that this reflected oncogene-induced damage 
arising from replication stress, synthesising the cell culture data and demonstrating a direct 
relevance to clinically derived cancer tissue72, 73. 
 
Tumour progression requires DNA damage response down-regulation. 
As discussed above, the notions that endogenous and exogenous DNA damage cause 
mutations leading to carcinogenesis, and that cancer avoidance necessitates active DNA 
repair mechanisms emerged as key early concepts in the aetiology of cancer. What emerged 
more slowly, however, was an appreciation that DDR mechanisms in general, as distinct from 
specific repair pathways per se, were essential for cancer avoidance. Initially based on studies 
of apoptosis, an important concept for our understanding cancer onset emerged – it was not 
necessarily the DNA damage itself that killed (or prevented the growth of) a cell, but rather 
the signalling pathways activated by such damage. Cell cycle checkpoint pathways, initially 
defined as systems that monitor genome integrity, are now understood to be pivotal in 
precluding the continued proliferation of damaged cells74. p53 plays a key role in this and the 
frequent loss of p53 function in tumours contributed to the emerging notion that DDR 
pathways must be down regulated to allow uncontrolled proliferation75.  
In 1997 Serrano proposed that expression of the Ras oncogene led to p53/p21 
activation that drives senescence or apoptosis. Thus, to achieve proliferation, the p53/p21 
pathways must become down-regulated in Ras expressing cells64. Similar findings were 
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observed following expression of the Myc oncogene, although in this case, proliferation 
necessitated down regulation of the ARF-Mdm2-p53 pathways76. Slightly distinct but related 
examples also followed, such as the demonstration that, although tumours in BRCA2+/- mice 
undergo loss of heterozygosity, the proliferation of homozygous BRCA2-deficient tumour 
cells demands additional mutations in spindle checkpoint genes77. The full breadth of the 
relevant pathways that require down-regulation and their significance in contributing to 
tumour progression subsequently slowly unravelled, as did the realisation that down-
regulation of these pathways could create a “mutator phenotype” causing genomic instability, 
as postulated many years earlier.  
 
Lessons from history 
Current models of cancer would argue that an initiating event(s), often caused by a mutation, 
leads to oncogene activation and ensuing replication stress. However, this must be coupled 
with subsequent down-regulation of DDR mechanisms - possibly by genetic alterations as a 
consequence of replication stress - to allow continued proliferation and continued genome 
instability - a prerequisite for a cancer cell to rapidly adapt to its ever-changing 
microenvironment.  Whilst this historical reflection has considered the time-line at which 
seminal concepts emerged, this does not reflect the order of events in the aetiology of cancer 
(Figure 1). Initiating event(s) causing oncogene activation most likely precede a state of 
replication stress, but it remains unclear if the DDR down-regulation is always directly 
caused by errors arising from replication stress or if this can precede it. The findings of 
Bartek and Halazonetis72, 73 that the up-regulation of the DDR occurs in precancerous lesions 
and that p53 mutations occur subsequently in late stage tumours, strongly support an order of 
events in which the onset of replication stress represents an early event, promoting the 
subsequent mutations that allow outgrowth.   
However, a more recent study involving ultradeep sequencing of cancer genes in sun-
exposed normal skin biopsies revealed a substantial accumulation of cancer driver mutations 
(with the characteristic signature of UV-induced mutations) that had undergone positive 
selection in the absence of evidence for cancer formation78. This suggests a different 
aetiology in which there is a strong initial selection to up-regulate growth-enhancing genes, 
and cells with such changes then await further steps leading to a genetically unstable state. 
The enhanced cancer predisposition caused by mutations in genes affecting both the early 
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(e.g. mutations enhancing an initiation event such as in xeroderma pigmentosum) and 
perceived late steps of cancer, (damage surveillance mechanisms such as in Li Fraumeni 
Syndrome) would be consistent with there not being a defined order of events leading to 
carcinogenesis. 
 Our historical reflection considers the many models or factors that have been 
proposed to contribute to carcinogenesis – viruses, epigenetic changes, DNA damaging 
agents, replication stressors and oxidative stress. Our current knowledge suggests that indeed 
all these factors are valid contributors, and they all merge into a model that leads ultimately 
to the generation of a genetically unstable state (Figure 2).  Strikingly, this pinpoints the 
enormous significance of the DDR processes: their importance was evident in the earliest 
studies, but has emerged to be far more substantial than originally predicted. Whilst early 
studies demonstrated that cells can recover from exposure to external DNA damaging agents 
revealing that they harbour DNA repair mechanisms20, perceptive scientists also saw that the 
DNA structure revealed by Watson and Crick could accumulate endogenously arising DNA 
damage, predicting that DNA repair pathways might be essential even during normal growth 
and metabolism79.  However, these early studies did not predict that the DDR mechanisms 
encompass not only DNA repair processes that seek to avoid the initiator mutations, but also 
DNA damage surveillance mechanisms that preclude the proliferation of genetically unstable 
cells. Further, an efficient replication machinery that restricts replication errors, and processes 
that allow recovery from the inevitable difficulties encountered during replication in a 
manner that maintains genomic stability are also required (Box 1). We now know that cancer 
cells not only down-regulate these pathways but often subvert them to fast track evolution 
and gain adaptability, the ultimate driver of carcinogenesis and metastasis80. 
 
The future 
Our historical reflections highlight the significance of the role played by the DDR processes 
in cancer aetiology. However, the plethora of DNA integrity surveillance, repair and 
signalling pathways, alongside their profound interconnectedness, has only been appreciated 
more recently. Similarly, the advent of tumour genome profiling by deep sequencing has only 
recently demonstrated that DDR genes are frequency mutated in all cancer types, with many 
individual pathways or genes found to be mutated in more than 50% of a specific cancer type 
(e.g. greater than 50% of ovarian cancers harbour mutations in HR genes)80, 81 (Figure 3).  
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The steps during carcinogenesis can be summarised as shown in Figure 2. While an 
understanding of these steps is of significant academic interest, it also provides a key tool for 
informed, targeted cancer therapy80.  The enhanced sensitivity of many cancer cells to DNA 
damaging agents, including radiation exposure, has been evident for many years, and indeed 
exploited for therapeutic benefit. The rationale for such sensitivity was poorly understood and 
unsatisfactorily often attributed to the more rapid growth of tumour cells. Consequently, the 
approach relied on serendipity, coupled with random trial and error. Our current knowledge 
of how the DDR pathways are changed in cancers is providing routes for more specific and 
rationally targeted therapy. A significant concept in this regard is that of synthetic lethality, 
where the goal is to identify a drug that will cause lethality to a cancer cell with inherent 
DDR defects whilst not harming a normal cell80, The foremost and very elegant example of 
exploiting a synthetically lethal genetic relationship is the treatment of breast cancers arising 
in BRCA1/2 deficient patients82. The key insight came from the realisation that BRCA1 and 
2 function during homologous recombination (HR), a key process that promotes replication 
fork stability, and that drug targeted inhibition of a specific enzyme (PARP1) confers a 
reliance on HR, and hence drug sensitivity82. Although such an approach might be anticipated 
to uniquely benefit BRCA1/2 defective patients, current studies revealing that HR can be 
downregulated in around 50% of ovarian cancers, dramatically expands the scope for such 
therapy81. A plethora of related studies are in progress, which include strategies to promote 
synthetic lethality based on such changes as the subversion of apoptosis, altered pathways of 
DNA double strand break repair, and loss of checkpoint arrest in cancer cells80, 82. 
Finally, to fully exploit the genome instability that is now recognised as an inherent 
property of most, if not all cancers, it is critical that we enhance both our understanding of the 
DDR pathways and exploit imaginative ideas to progress cancer treatment.  Ironically, 
however, our understanding of the stages of carcinogenesis has also provided an explanation 
for why our targeted therapies will frequently fail.   
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Figure Legends. 
Figure 1: Time line showing when key concepts and findings relating to cancer development 
emerged. (currently shown as a and b but will be merged). 
 
Figure 2: How the DDR pathways impact upon steps leading to cancer. 
A depiction of how changes in the DDR pathways promote critical steps in the aetiology of 
carcinogenesis.   
 
Figure 3: Many DDR proteins are mutated in cancer. 
Data from the Cancer Genome Atlas has revealed the extent to which mutations in DDR 
proteins are observed in cancers. These changes differ for different tumour sites. A) shows a 
radial plot, where the radius length indicates the proportion of patients with protein coding 
mutations predicted to be impacting in each cancer type. All mutations included are present 
in at least two distinct patient samples. The concentric circles indicates the percentage of 
patients affected. B) shows copy-number variation in the different DDR pathways (red, loss 
of gene-copies; blue, amplification of genes C) expression level variation in DDR pathways. 
Red, decreased expression; Blue, increased expression. Pathways are: AM, alternative 
mechanism for telomere maintenance; BER, base excision repair; CPF, checkpoint factor; 
CR, chromatin remodelling; CS, chromosome segregation; DR, direct repair; FA, Fanconi 
anaemia pathway; HR, homologous recombination; MMR, mismatch repair; NER, nucleotide 
excision repair; NHEJ, non-homologous end joining; OD, other double-strand break repair; 
TLS, translesion synthesis; TM, telomere maintenance; UR, ubiquitylation response. 
 
Box 1:  DDR processes of relevance for Cancer 
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Data for the time line figure (currently shown as two figures a, b – they will be 
combined) 
Green are key concepts: yellow are key findings 
 
1.  Environmental exposure can cause cancer.  
1775   
6 
 
2..  Concept of hereditary material    
1900-1950. 
1-4. 
 
3.  Helical structure of DNA   
1953  
8, 9 
 
4.  Link between mutagenesis and carcinogenesis. Cancer proposed to be caused by DNA 
mutations.     
1900-1961 specific link to 1961  
2, 10, 11. 
 
5.    Alklyating agents react with and damage DNA 
 1960 
 10 
 
6.  DNA can be damaged by endogenous and exogenous agents.  
1900-1961  
4, 10, 79.   
 
7.  DNA damage can be repaired. 
 Circa 1958 
83(for a review see 20) 
 
8  XP identified as the first DNA repair disorder.  
 1969, 
 23 
 
9 DNA repair defective disorders are cancer prone; including Bloom’s Syndrome and 
Fanconi anaemia. Hence failure to repair DNA contributes to cancer 
 1969-2015 
 23, 31   
 
 
10.  Viruses proposed as a major cause of cancer. 
 1975-1985  
56, 57.  
 
11.  Cell cycle checkpoints proposed. 
22 
 
1989 
84 
 
12.  Concept of caretaker and gate keeper genes. 
 1997 
85 
 
13.  Acquired capability of cancers. 
 2000 
 86 
 
14.  Concept of oncogenes. 
 1981 
 59. 
 
15.  Concept of tumour suppressors 
 1984 
87 
 
16 Significance of replication stress and replication fork stability appreciated. 
2005 
72, 73. 
 
 
17  Oncogene expression causes replication instability. 
1999 
70 
  
18.  Wylie and co-workers define the process of apoptosis. 
1972. 
88 
 
19.  AT is a radiosensitive disorder with cancer predisposition. 
1975 
89 
 
20.  Microsatellite instability identified in LS tumours and shown to be due to :MMR 
deficiency. MSH2 identified as 1st LS locus. 
 1993 
 24, 25 
 
21.  Mutator phenotype for cancer cells proposed. 
 1974 
 47 
 
22,  BRCA1/2, which are mutated in hereditary breast cancer, function in HR. 
23 
 
 1997-1999. 
90-93 
 
23.  Ames test established to identify carcinogens via analysis of mutagens. 
1974 
13 
 
24.  p53 mutations identified in cancers. Role of p53 dependent surveillance pathways 
recognised as suppressing cancers. 
 1990. 
46, 74 
 
 
25.  Oncogenes expression leads to p53/p21 activation, senescence or apoptosis. 
 1997 
64. 
 
26.  Oncogene expression causes deregulated metabolism leading to ROS and DNA 
damage. 
 2002-2003 
 66, 67 
 
 
27.  DDR is an anti cancer barrier in early stage tumourogenesis; mutations in DDR 
genes in later stage tumours 
72, 73 
 
 
28.  Multiple mutations in DDR genes identified in cancers. 
2014 
80, 81   
 
Box 1. DDR processese of relevance for Cancer.   
1) DNA repair. 
There are multiple DNA repair pathways, with sub-pathways providing lesion specificity. Nucleotide 
Excision Repair (NER) removes bulky DNA lesions; DNA non-homologous end-joining and 
homologous recombination (HR) repair DNA double strand breaks (DSBs); Mismatch repair (MMR) 
corrects mismatched base pairs; Base excision repair (BER) repairs damaged bases and links to single 
strand break (SSB) repair. Mutations in these pathways in patients enhance cancer susceptibility. 
2) Damage Response Signalling. 
There are two DDR signalling pathways. ATM-dependent signalling is activated by DSBs; ATR-
dependent signalling is activated by single stranded DNA. DDR signalling can activate apoptosis, 
checkpoint arrest and influence DNA repair. Mutations in ATM signalling components in patients 
confers cancer susceptibility. However, ATR-deficient mice do NOT get tumours. 
3) Cell cycle checkpoints. 
DNA integrity is constantly monitored with DNA damage triggering a checkpoint response that 
prevents cell cycle progression. Arrest can be permanent or transient. Checkpoints prevent entry 
from G1/S, G2/M and an intra-S phase checkpoint regulates fork progression or origin firing. Many 
tumours have inactivated checkpoint responses.  
 
4) Apoptosis. 
Apoptosis represents a programmed cell death pathway, which functions in some tissues during 
normal development but also prevents proliferation of damaged cells. Apoptosis can be p53 
dependent or independent. p53 is commonly mutated in cancer. 
5) Fidelity of replication. 
Multiple processes function to maintain the accuracy of replication and enhance recovery from 
replication fork stalliing or collapse. Homologous recombination (HR) plays a key role and HR genes 
are commonly mutated in cancers. 
6) DNA re-replication.  
Re-replication can cause aneuploidy and subsequently genomic instability. Several mechanisms 
prevent DNA re-replication. 
 
7) Telomere length. 
Shortened telomeres lead to senescence; cancer cells need to maintain telomere length. Activation 
of telomerase or an alternative pathway (ALT) to maintain telomere length in cancers is common. 
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